Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig T Jordan

Showing results (111-120 of 164) with videos related to

Pageof 17
Sort By:
Cell Stem Cell|January 22, 2013
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cellsEleni D Lagadinou, Alexander Sach, Kevin Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based TherapyZachary J Walker, Beau M Idler, Lorraine N Davis, et al.
The Journal of Clinical Investigation|March 2, 2016
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemiaSimone S Riedel, Jessica N Haladyna, Matthew Bezzant, et al.
Cancer Cell|February 13, 2019
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem CellsCourtney L Jones, Brett M Stevens, Angelo D'Alessandro, et al.
JCI Insight|December 3, 2020
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunityAlisa B Lee-Sherick, Kristen M Jacobsen, Curtis J Henry, et al.
Blood Advances|October 5, 2021
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaEvan M Cherry, Diana Abbott, Maria Amaya, et al.
Cancer Cell|November 14, 2018
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem CellsCourtney L Jones, Brett M Stevens, Angelo D'Alessandro, et al.
JCI Insight|November 3, 2018
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunityAlisa B Lee-Sherick, Kristen M Jacobsen, Curtis J Henry, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Cancer|April 22, 2021
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cellsBrett M Stevens, Courtney L Jones, Daniel A Pollyea, et al.
Pageof 17

Showing results (111-120 of 164) with videos related to

Sort By:
Pageof 17
Cell Stem Cell|January 22, 2013
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cellsEleni D Lagadinou, Alexander Sach, Kevin Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based TherapyZachary J Walker, Beau M Idler, Lorraine N Davis, et al.
The Journal of Clinical Investigation|March 2, 2016
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemiaSimone S Riedel, Jessica N Haladyna, Matthew Bezzant, et al.
Cancer Cell|February 13, 2019
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem CellsCourtney L Jones, Brett M Stevens, Angelo D'Alessandro, et al.
JCI Insight|December 3, 2020
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunityAlisa B Lee-Sherick, Kristen M Jacobsen, Curtis J Henry, et al.
Blood Advances|October 5, 2021
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaEvan M Cherry, Diana Abbott, Maria Amaya, et al.
Cancer Cell|November 14, 2018
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem CellsCourtney L Jones, Brett M Stevens, Angelo D'Alessandro, et al.
JCI Insight|November 3, 2018
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunityAlisa B Lee-Sherick, Kristen M Jacobsen, Curtis J Henry, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Cancer|April 22, 2021
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cellsBrett M Stevens, Courtney L Jones, Daniel A Pollyea, et al.
Pageof 17